01 6Allergan Inc.
02 2Galderma Canada Inc.
Patent Expiration Date : 2014-09-19
Date Granted : 2006-05-02
Brand Name : ALPHAGAN
Patent Number : 2173974
Filing Date : 1994-09-19
Strength per Unit : 0.2%
Dosage Form : Ophthalmic Solution
Human Or VET : Human
Route of Administration : Topical, ocular
Patent Expiration Date : 2014-09-19
Date Granted : 2006-05-02
Patent Expiration Date : 2016-06-17
Date Granted : 2002-09-03
Brand Name : ALPHAGAN
Patent Number : 2225626
Filing Date : 1996-06-17
Strength per Unit : 0.2%
Dosage Form : Ophthalmic Solution
Human Or VET : Human
Route of Administration : Topical, ocular
Patent Expiration Date : 2016-06-17
Date Granted : 2002-09-03
Patent Expiration Date : 2014-09-19
Date Granted : 2006-05-02
Brand Name : ALPHAGAN
Patent Number : 2173974
Filing Date : 1994-09-19
Strength per Unit : 0.5%
Dosage Form : Ophthalmic Solution
Human Or VET : Human
Route of Administration : Topical, ocular
Patent Expiration Date : 2014-09-19
Date Granted : 2006-05-02
Patent Expiration Date : 2016-06-17
Date Granted : 2002-09-03
Brand Name : ALPHAGAN
Patent Number : 2225626
Filing Date : 1996-06-17
Strength per Unit : 0.5%
Dosage Form : Ophthalmic Solution
Human Or VET : Human
Route of Administration : Topical, ocular
Patent Expiration Date : 2016-06-17
Date Granted : 2002-09-03
Patent Expiration Date : 2014-09-19
Date Granted : 2006-05-02
Brand Name : ALPHAGAN P
Patent Number : 2173974
Filing Date : 1994-09-19
Strength per Unit : 0.15%
Dosage Form : Ophthalmic Solution
Human Or VET : Human
Route of Administration : Topical, Ocular
Patent Expiration Date : 2014-09-19
Date Granted : 2006-05-02
Patent Expiration Date : 2016-06-17
Date Granted : 2002-09-03
Brand Name : ALPHAGAN P
Patent Number : 2225626
Filing Date : 1996-06-17
Strength per Unit : 0.15%
Dosage Form : Ophthalmic Solution
Human Or VET : Human
Route of Administration : Topical, Ocular
Patent Expiration Date : 2016-06-17
Date Granted : 2002-09-03
